<div><div></div><div><span><p><span>Amy L. Burroughs, Chief Executive Officer and Director at Terns Pharmaceuticals, sold 71,339 shares of common stock on January 5, 2026, at a weighted average price of $38.103 per share, totaling $2,718,229. Following the transaction, Burroughs directly owns 138,976 shares and indirectly owns 8,319 shares through the Amy L Burroughs 2017 Trust.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Burroughs Amy L.</span></td></tr><tr><td><span>Relationship</span></td><td><span>Chief Executive Officer</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$2,718,229</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>SEC Filing: </span>Terns Pharmaceuticals, Inc. [ TERN ] - Form 4 - Jan. 06, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

TERN

<p>Amy L. Burroughs, CEO of Terns Pharmaceuticals, sold 71,339 shares of common stock on January 5, 2026, for a total of $2,718,229 at a weighted average price of $38.103 per share. After the sale, she retains ownership of 138,976 shares directly and 8,319 shares indirectly through the Amy L Burroughs 2017 Trust. This transaction was reported in SEC Form 4.</p>

Terns Pharmaceuticals CEO Amy L. Burroughs Sells Shares